RALEIGH, N.C. — Voyager Pharmaceutical’s lead product has shown promise in a Phase II clinical trial, the company said Tuesday.

Leuprolide acetate, the active ingredient in VP4896 which is Voyager’s lead product, stabilized the cognitive and functional decline of women with mild-to-moderate Alzheimer’s disease when used in conjunction with standard Alzheimer’s therapy, the company said.

Women ages 65 and older with mild-to-moderate Alzheimer’s were included in the trial.

Leuprolide acetate has been used for over 20 years as a treatment for prostate cancer.

Voyager: www.voyagerpharma.com